Jonathan has over 20 years of experience in the biotech/pharma industry focused on strategic partnerships (investments, licensing and M&A) to progress development of new therapeutics. Prior to joining Kynos, Jonathan was founding CEO of Syndesi Therapeutics, raising finance and building a team to develop a small molecule through early clinical development as a potential treatment for cognitive deficits associated with Alzheimer’s and other disorders. Syndesi was acquired by AbbVie in March 2022 for a total deal value of up to $1 BN. Prior to joining Syndesi Therapeutics, Jonathan worked at various biotech companies in senior business and corporate development roles, including Evotec, Bicycle Therapeutics and Proximagen. During this time he led numerous varied partnership deals with pharma and biotech companies across both pre-clinical and clinical stage assets. Jonathan has a scientific background. Following his PhD in Pharmacology and Neuroscience, he held a research position at Novartis, prior to moving into business/corporate development.